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ABSTRACT
Background
Neural stem cells are currently being investigated as potential therapies for neuro-
degenerative diseases, stroke, and trauma. However, concerns have been raised over the safety
of this experimental therapeutic approach, including, for example, whether there is the
potential for tumors to develop from transplanted stem cells.
Methods and Findings
A boy with ataxia telangiectasia (AT) was treated with intracerebellar and intrathecal
injection of human fetal neural stem cells. Four years after the first treatment he was diagnosed
with a multifocal brain tumor. The biopsied tumor was diagnosed as a glioneuronal neoplasm.
We compared the tumor cells and the patient’s peripheral blood cells by fluorescent in situ
hybridization using X and Y chromosome probes, by PCR for the amelogenin gene X- and Y-
specific alleles, by MassArray for the ATM patient specific mutation and for several SNPs, by PCR
for polymorphic microsatellites, and by human leukocyte antigen (HLA) typing. Molecular and
cytogenetic studies showed that the tumor was of nonhost origin suggesting it was derived
from the transplanted neural stem cells. Microsatellite and HLA analysis demonstrated that the
tumor is derived from at least two donors.
Conclusions
This is the first report of a human brain tumor complicating neural stem cell therapy. The
findings here suggest that neuronal stem/progenitor cells may be involved in gliomagenesis
and provide the first example of a donor-derived brain tumor. Further work is urgently needed
to assess the safety of these therapies.
The Editors’ Summary of this article follows the references.
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Research in recent years has demonstrated that neuro-
genesis constitutively occurs in speciﬁc regions of the adult
mammalian brain and that there are substantial numbers of
multipotent stem/precursor cells from many parts of the
brain that may be used therapeutically [1–4]. The fetal brain,
characterized by active neurogenesis, has been suggested to
be a promising source of therapeutic neural stem cells [5].
Neural stem cells are being investigated as potential therapies
for neurodegenerative diseases, stroke, and trauma [1–4,6–9].
Such cells have also been suggested as potential therapies for
infants and children affected by genetic and acquired diseases
characterized by neurological deterioration [1,5].
Neural tissue-derived stem cells, phenotype-speciﬁed pro-
genitor cells derived from pluripotential embryonic stem
cells (ESC), and neural cells derived from various trans-
differentiated non-neural stem cells have all been inves-
tigated in preclinical studies for their ability to generate
neurons and glia [1,3–5], and the use of neural stem cells in
clinical trials has been described [10].
However, there are potential dangers associated with stem
cell therapy, such as malignant transformation [2,3]. The
injection of pluripotent ESC or ESC-derived precursor cells
in rodents leads frequently to the development of teratomas
or teratocarcinomas [6,11,12], although the tumorigenic
potential of ESC seems to be greatly reduced when cells are
predifferentiated in vitro before implantation [7,8,13].
Importantly, ESCs seem more prone to generate tumors
when implanted into the same species from which they were
derived [11]. Therefore it has been noted that the absence of
tumors after implantation of human stem cells into rodents
does not exclude their occurrence in the human brain [2].
Recently the use of human ESC-derived dopaminergic
neurons enriched by coculture with telomerase-immortalized
midbrain astrocytes resulted in undifferentiated expansion
suggesting there was a potential for tumor development when
injected to rodents [14].
We describe here a patient affected by the neurodegener-
ative hereditary disorder ataxia telangiectasia (AT) who was
treated by repeated transplantations of fetal neural stem cells
and who developed a multifocal brain tumor.
Methods
Fetal Neural Stem Cell Isolation and Preparation
Isolation, preparation, and characterization of fetal neural
stem cells were performed as published [15] and described in
Text S1. The details are derived from a medical report
describing the procedure and the protocol for the isolation
and preparation of the transplanted cells, which were given
to the parents of the patient.
Pathology
The specimen was ﬁxed in 10% neutral buffered formalin,
routinely processed, and embedded in parafﬁn. It was cut at 5
lm for histochemical (hematoxylin–eosine, Luxol fast blue-
PAS, Masson trichrome) and immunohistochemical staining
(streptavidin-biotin peroxidase complex method). Antisera
were directed against S-100 protein (Dako; 1:1,600, polyclonal),
glial ﬁbrillary acidic protein (GFAP) (Dako; 1:4,000, polyclo-
nal), neuroﬁlament protein (NF) (Dako; 1:800, 2F11), synapto-
physin (ICN; 1:40, SY38), Neu-N (Chemicon; 1:10,000),
epithelial membrane antigen (EMA) (Dako; 1:50, E29), p53
protein (Dako; 1:2,000, DO7), and Ki-67 antigen (Dako; 1:300,
MIB-1).
Combined Analysis of Morphology and Interphase
Fluorescence In Situ Hybridization
Morphology and interphase ﬂuorescence in situ hybrid-
ization (I-FISH) of cells obtained from touch preps of the
resected tumor at the single cell level were viewed using the
Duet multiparametric imaging system (Bioview) as previously
described [16]. May Grunwald Giemsa (MGG)-stained touch
preps were scanned, and coordinates and images of all the
cells were saved for comparison with FISH analysis. Slides
were destained and an I-FISH procedure with a CEP XY DNA
probe kit (Vysis) was applied: X chromosome, Spectrum-
Green; Y chromosome, SpectrumOrange.
The ﬂuorescent signals in the speciﬁc cells were viewed in
parallel with the morphology of the same cells scanned
previously (original magniﬁcation 31,000).
MALDI-TOF Mass Spectrometry Genotyping of the ATM
C103T Mutation and SNPs
Detection of the ATM C103T mutation [17] and genotyping
of 24 SNPs including the rs7294 (VKORC1 9041G/A) [18] were
carried out using the SEQUENOM MassArray MALDI-TOF
mass spectrometer. Genomic DNA was extracted from blood
samples, buccal smear (BS), tumor tissue, and laser capture
microdissection (LCM)-isolated tumor cells. Homogenous
mass EXTEND (hME) assays were designed according to the
manufacturer’s protocol. Each assay involves PCR ampliﬁca-
tion of the region containing the mutation/SNP of interest,
Shrimp Alkaline Phosphatase treatment to remove excess
dNTPs, addition of DNA polymerase along with a mixture of
dideoxy and deoxy NTPs that allows extension of the hME
primer through the mutation/polymorphic site and generates
allele-speciﬁc extension products. This step is followed by
cleanup of the extension reaction to remove salt, spotting of
the extension product into 384 Sequenom proprietary
SpectroCHIP, and the analysis of the spotted product using
the MALDI-TOF mass spectrometry.
Sequences of the oligonucleotides used for the detection of
the ATM mutation and SNPs using the Sequenom MassArray
are provided in Table S1.
PCR of Tetranucleotide Repeats and Amelogenin
Homologous X and Y Alleles
Multiplex tetranucleotide repeat PCR was performed on 2
ng of genomic DNA using the AmpFlSTR SGM Plus kit
(Applied Biosystems), which contains tetranucleotide repeat
loci plus the X-Y homologous gene amelogenin labeled in
three different colors (blue, 5-FAM; green, JOE; and yellow,
NED). Ampliﬁed PCR products were subjected to capillary
electrophoresis in an ABI Prism 3100 (Applied Biosystems)
automated DNA sequencer using the conditions recommen-
ded by the manufacturer. The GeneScan 3.7 Analysis software
(Applied Biosystems) was used for the analysis of the PCR
products.
Human Leukocyte Antigen Typing
Human leukocyte antigen (HLA) typing was determined
from DNA samples extracted from peripheral blood (PB), BS,
and the tumor, and from cloned ampliﬁed HLA A*, B*, and
DRB1* alleles from the tumor using the primers described in
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supplied by QIAGEN. Following the cloning procedure DNA
was extracted and samples were typed for HLA A*, B*, and
DRB1*. The methodologies used for HLA typing were
reverse-sequence speciﬁc oligonucleotide probes (SSOP)
using the Luminex platform with kits supplied by Tepnel.
LCM of Tumor Cell Nuclei
LCM of tumor cell nuclei was performed using the PALM
Microbeam laser system from 5-lm-thick sections of parafﬁn
embedded tissue stained with hematoxylin–eosine placed on
membrane-coated slides.
Results
Report of Case
The patient’s parents gave written informed consent (as
outlined in the PLoS consent form, http://journals.plos.org/
plos_consent_form.pdf) to publication of his case details. In
addition, the parents have conﬁrmed to the authors that the
patient is aware of the existence of the complication
described in this paper and that he is aware it is discussed
in a scientiﬁc publication, which is available on the internet.
A 13-y-old boy with AT, who is homozygous for the North
African Jewish C103T ATM gene mutation presented to the
Sheba Medical Center in February 2005 with recurrent
headaches. On examination he had severe neurological
deﬁcits characteristic of AT, affecting mainly his motor
functions and making him wheelchair bound. The patient’s
intelligence was normal and he is highly motivated at school
and socially active. His recent detailed immunologic and
hematological status is given in Table S2. Since the age of 7 y
he has been treated for hypogammaglobulinemia at the Sheba
Medical Center with monthly intravenous immunoglobulin.
In May 2001 at the age of 9 y, in March 2002 at the age of 10
y, and in July 2004 at the age of 12 y, he was taken by his
parents to be treated in Moscow with repeated trans-
plantation of fetal stem cells (see Text S1 for details as
supplied to the parents by the patient’s physicians in
Moscow). The treating team at the Sheba Medical Center
was not involved in this treatment.
MRI performed in February 2005 to investigate the
headaches revealed a right infratentorial lesion slightly
compressing the brain stem and another lesion at the cauda
equina (Figure 1A and 1B). The lesions grew slowly as
evidenced by repeat MRIs in June and July 2006. In
September 2006 at the age of 14 y, surgery was performed
and a tumor localized at L3–4 level attached to the cauda
equina nerve roots was removed. Additional ‘‘satellite’’
lesions were identiﬁed attached to nerve roots rostral to the
main lesions (Figure 2A and 2B).
Since surgery the patient’s general condition has remained
stable. During follow up there has been slow growth of the
tumor adjacent to the right infratentorial lesion with some
compression on the brain stem. MRI of the infratentorial
tumor at diagnosis and in January 2008 illustrates that the
mass has more than doubled in volume (Figure S1). MRI of
the spinal cord in July 2007 did not reveal signiﬁcant growth
compared to the postoperative imaging and there is no overt
clinical deterioration. Based on the pathology and since
patients with AT are extremely sensitive to chemotherapy
and radiotherapy it was decided to follow up the patient
conservatively and to repeat surgery only if indicated by
clinical deterioration.
Histology
The specimen consisted of three fragments of tumor
ranging in size from 0.4 to 1 cm in greatest dimension. The
pathology specimen (Figures 3–5) consisted almost entirely of
glioneural tumor and only in small part of a remnant of the
proximal ﬁlum terminale accompanied by scant benign
adipose tissue, a not uncommon incidental ﬁnding at that
Figure 1. Pre-Operative MRI
(A) Brain MRI (T2) demonstrating a lesion (arrow) based on the tentorium,
next to the brain stem (BS).
(B) Spinal-lumbar MRI (T2) showing intradural lesion (arrow), at the level
of the L4 vertebra.
doi:10.1371/journal.pmed.1000029.g001
Figure 2. Intra-Operative View
(A) The main lesion situated within the cauda equina nerve roots (I, the
main tumor bulk; II, nerve root entering the tumor; III, normal nerve root).
(B) One lumbar level above the main lesion, several ‘‘satellite’’ lesions are
seen adherent to the caudal nerve roots (I, II, III, satellite tumors rostral to
the main tumor bulk).
doi:10.1371/journal.pmed.1000029.g002
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characterized by vague nodules of neurons and accompany-
ing glial cells. The latter, consisting largely of astrocytes,
formed a circumferential rind about the lesion and served to
demarcate ill-deﬁned aggregates of intermingled neurons
and astrocytes. The neurons, all relatively mature, varied in
cytologic characteristics to include (a) medium size neurons
with open chromatin, small nucleoli, and relatively small
quantities of pale cytoplasm lacking Nissl substance and (b)
sizeable neurons with larger nuclei, distinct nucleoli, more
amphophilic cytoplasm, and discernible Nissl substance.
Neuronal dysmorphism, including binucleation, was infre-
quent. Staining for both synaptophysin and neuroﬁlament
protein was noted only in association with the neurons and
their processes. Also conspicuous were two glial elements,
one ependymal and the other astrocytic in nature. Compris-
ing much on one tissue fragment, the monomorphous
ependymal cells were tanycytic in appearance, featuring
elongate nuclei and very long, aligned, heavily ﬁbrillated
processes. In contrast, the astrocytes possessed oval nuclei,
eccentric cytoplasm, and scant processes. Immunohistochem-
ical stains showed strong s-100 protein and glial ﬁbrillary
acidic protein (GFAP) reactivity in the glial element.
Epithelial membrane antigen (EMA) staining was scant and
took the form of rare, paranuclear dots within the cytoplasm
of the ependymal cells.
The entire lesion was unassociated with cytologic malig-
nancy, mitotic activity, microvascular proliferation, or
necrosis. Low to moderate strength p53 staining was seen in
40% of astrocytic and 40% of ependymal cells. The MIB-1
preparation showed very low level staining (1%). Also
indicative of slow lesion growth was the ﬁnding of vascular
hyalinization, a feature accentuated on Masson trichome
stain.
Cytogenetic and Molecular Analysis of Tumor
The occurrence of a tumor following administration of
neural stem cells and the unusual presentation of an extra-
Figure 3. Hematoxylin–Eosine Staining of the Tumor
(A) The bulk of the specimen consisted of ill-defined lobules of glioneuronal cells.
(B) These cells are best seen on Masson trichome stain.
(C) At medium power glioneuronal cell circumscription by astroglial cells is apparent.
(D) The centers of the lobules consist of two cell types, including pale neurons with large round nuclei, open chromatin, and a distinct nucleolus as well
as smaller, astrocytic cells with more hyperchromatic nuclei and pale cytoplasm.
doi:10.1371/journal.pmed.1000029.g003
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injection sites raised the possibility of a donor-derived tumor.
In order to explore this possibility cytogenetic and molecular
approaches were used. Since the patient is affected by AT,
known to be characterized by genetic instability [19], we used
several complementary methodologies to prove that the
nonidentity of the tumor and the patient is not due to
chromosomal and genetic instability. FISH using X- and Y-
chromosome speciﬁc probes on touch preps from the tumor
biopsy revealed that the tumor removed from the male
patient is composed of both XX and XY cells (Figure 6A).
Analysis of the homologous amelogenin gene X- and Y-
speciﬁc alleles in the patient’s PB and tumor reveals that,
while in the PB the signals from the two alleles are equal, in
the tumor the X allele signal intensity is three times that of
the Y allele (Figure 6B). This result further supports the
presence of cells originating from a female donor. Analysis of
the ATM gene North African Jewish C103T mutation using
the SEQUENOM MassArray (Figure 7A) identiﬁed both
parents of this patient as heterozygous for this mutation
while homozygosity was demonstrated in the patient’s PB and
BS. Analysis of DNA extracted from undissected tumor
revealed the presence of both the mutant and the normal
allele. DNA extracted from LCM isolated tumor cells (Figure
S2) carried only the normal allele, and the mutant allele is not
detected, proving that the tumor is of donor origin. We
analyzed 24 known SNPs using the SEQUENOM MassArray
on DNA samples from the tumor, the patient’s PB and BS,
and the parents’ PB (list of all SNPs tested is given in Table
S1). Three SNPs, rs1043550, rs7294, and rs1061170, were
informative and identiﬁed a tumor-speciﬁc allele that is not
present in the patient PB or BS. One of them, rs7294
(VKORC1 9041G/A), proves conclusively that the tumor
genotype could not originate from the patient or his parents.
Figure 7B shows the analysis of this SNP in the DNA obtained
from the tumor biopsy and in LCM isolated tumor cells, in
comparison to the pattern observed in PB of the patient and
his parents. The patient and his parents are homozygous for
the A allele, the undissected tumor revealed the presence of
both the A and G alleles, while DNA extracted from LCM
isolated tumor cells carried only the G allele. This result
further supports the fact that the tumor is of nonhost origin
Figure 4. Immunohistochemistry of the Tumor
(A) Immunohistochemical staining of the cells comprising the nodules show abundance of neurons as evidenced on synaptophysin, (B) neu N, and (C)
neurofilament protein preparations.
(D) The stromal astrocytes show cytoplasmic reactivity for glial fibrillary acidic protein.
doi:10.1371/journal.pmed.1000029.g004
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by showing that the nonhost allele is not represented in the
parental germline [20].
Analysis with polymorphic microsatellite tetranucleotide
repeat markers of DNA from the tumor and DNA extracted
from PB and BS obtained from the patient clearly showed
that a number of alleles of nonhost origin are present in the
tumor (Figure 8A and Table S3). The number of nonrecipient
alleles detected in the tumor indicates that more than one
donor cell population is present. A possible alternative
explanation for the presence of additional variants in the
DNA microsatellite proﬁle in tumors is genomic instability
resulting from mismatch repair defect [21]. We therefore
investigated further the number of possible donors present in
the tumor by detailed HLA analysis. HLA typing of the
patient’s PB and BS, and the tumor biopsy is shown in Figure
8B. The analysis conclusively identiﬁed the presence of two
HLA A*, four HLA B*, and four HLA DRB1* nonhost alleles
in the tumor. The presence of additional HLA A*, B*, and
DRB1* alleles not present in the patient germline HLA or in
his parents, conﬁrms the presence of nonhost donor cells in
the tumor. The presence of four additional alleles of HLA B*
and DRB1* conﬁrms the presence of cells originating from at
least two donors.
Discussion
We describe here a patient with AT who was treated
repeatedly with fetal neural stem cells and who developed a
multifocal brain tumor. Histology and immune phenotyping
of the resected mass led to the diagnosis of a glioneuronal
tumor. This is the ﬁrst report of a human brain tumor
developing from transplanted neural stem cells. The results
obtained from the various cytogenetic and molecular studies
performed on the tumor led us to conclude that the tumor is
derived from the neural stem cells obtained from at least two
aborted fetuses that were administered a few years earlier.
This case therefore conﬁrms that the concerns raised
regarding the risk of tumor development resulting from
therapeutic transplantation of neural stem/precursor cells
were not unfounded.
The cellular composition of the glioneural tumor encoun-
Figure 5. Histology and Immunohistochemistry of the Tumor
(A)Theminorelementofthetumorconsistsofmarkedlyelongateependymalcells(tanycytes)withrefractile,fibril-richprocessesterminatinguponthestroma.
(B) Note strong staining for S-100 protein, and (C) glial fibrillary acidic protein.
(D) Scattered dot-like paranuclear microlumens, a feature of ependymal cells, show epithelial membrane antigen reactivity.
doi:10.1371/journal.pmed.1000029.g005
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neuronal stem cells. Glia and neurons, the two principal cell
types comprising the central nervous system, were both
represented and well differentiated. Unlike conventional
glioneuronal tumors occurring spontaneously in the human
nervous system, the glial element of this patient’s tumor was
bitypic, including not only astrocytes but ependymal cells as
well. Ependymal cells are only rarely encountered in
association with neurons in human mixed glial and neuronal
tumors [22]. The benign, morphologically mature nature of
the sampled tumor could only be a reﬂection of differ-
entiation and maturation.
The slow but demonstrated growth of both this patient’s
lesions is in keeping with the low MIB-1 labeling index noted.
Lacking a biopsy of the subtentorial tumor, the histogenetic
relationship to the biopsied tumor remains to be determined.
The similar growth rate of both processes suggests that both
may be glioneuronal in nature. As separate stem cell
injections were involved in the proximity of the two lesions
there is no need to postulate spinal seeding of the intra-
cranial tumor to the lumbar sac. The multiple lumbar sac
deposits may be entirely independent and morphologically
distinct, their occurrence representing multifocal implanta-
tion at the time of stem cell injection rather than a
manifestation of seeding of a single implant.
The slow growth of the tumors, the benign character of the
biopsied tumor, and the low MIB-1 labeling index suggest a
favorable prognosis, although it should be noted that all
available information regarding the clinical behavior of such
tumors is based on endogenous tumors and does not
necessarily reﬂect the clinical behavior of a tumor of
exogenous origin.
While most naturally occurring tumors are monoclonal,
cancers developing in exceptional situations favoring tumori-
genesis are often oligo- or multiclonal. For example,
embryonal tumors such as retinoblastoma occurring in
individuals carrying a germline mutation in a tumor
suppressor gene [23] and virally induced malignancies such
as Epstein-Barr virus (EBV)-related post-transplant lympho-
proliferative diseases [24] often contain several distinct
clones. The therapeutic use of fetal neural stem cells derived
from several donors and treated in vitro by growth factors in
the described case may have created a high risk situation
where abnormal growth of more than one cell occurred.
Germinal regions such as the subventricular zone have long
been proposed as the areas where gliomas originate. In
animal models, regions of the brain with stem cell popula-
tions are more sensitive to chemical or viral oncogenesis than
areas with a low proportion of proliferating cells [25,26].
While neoplastic transformation of fully differentiated glia is
widely assumed to be involved in gliomagenesis, this report
describing the development of a glioneural neoplasm from
transplanted neural stem cells supports an alternative
mechanism, namely the development of the tumor from
neural stem/progenitor cells [25,26]. It is possible that the in
vitro expansion of fetal neural stem cells in conditioned
medium supplemented with growth factors such as bFGF and
EGF promoted transformation [27]. In addition it is possible
that neuronal stem cells injected to ectopic sites where they
are free of normal developmental control mechanisms
provided by the physiological microenvironment may under-
go abnormal growth and differentiation.
In recent years the possibility of transmission and engraft-
ment of malignant and premalignant cells has emerged as an
important mechanism for cancer development and propaga-
tion [28]. We have shown that all canine transmissible
venereal tumors (TVT) originate from the same tumor and
spread by malignant cell transplantation [29,30]. Another
illustrative model for transplanted tumors is the Tasmanian
devil facial-tumor disease [31]. Donor origin tumors have also
Figure 6. Analysis of X and Y Chromosomes of the Tumor Cells Using I-FISH and PCR Analysis of the Amelogenin X- and Y-Specific Alleles Showing the
Presence of Female Cells in the Tumor
(A) Combined analysis of morphology and I-FISH with X chromosome (SpectrumGreen) and Y chromosome (SpectrumOrange) probes on tumor touch
preps. Upper panels, May Grunwald Giemsa-stained cells; lower panels, I-FISH analysis of the cells appearing in the upper panel. Two green signals
indicate female cells (XX). One green and one orange signal indicate male cells (XY).
(B) PCR analysis of the X chromosome and Y chromosome amelogenin homologous alleles in the patient’s PB and tumor (T).
doi:10.1371/journal.pmed.1000029.g006
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transmission of cancer [28,32] and in solid organ transplant
recipients [33]. In the majority of such cases of tumor
transplantation immune surveillance failure can be attrib-
uted to immunodeﬁciency. The patient described, like other
AT patients, suffers from immune deﬁciency, which may have
prevented rejection of the transplanted cells. This immuno-
deﬁciency may explain the persistence of donor cells from at
least two donors several years after the experimental therapy.
In some transplanted tumor models such as the TVT,
donor-derived tumor can subsequently regress because of
immune rejection. Such results suggest that modulation of
the immune system could be a possible future therapy in the
patient described here. However, the immune deﬁciency of
our patient is not severe (see Table S2), which suggests that
even relatively immunocompetent patients may also fail to
reject neural stem cells and be at risk for tumor development.
In addition, a child’s developing central nervous system may
provide an environment that promotes tumorigenesis,
especially in combination with the abnormal AT host
environment characterized by deranged cellular responses
to stress. Cases of astrocytoma have been reported in children
with AT [34].
Studies of leukemia in monozygotic twins and screening of
neonatal blood samples for leukemia-speciﬁc genetic aberra-
tions have shown that in most childhood leukemias prema-
lignant cells are already present in utero [35]. It usually takes
months or years for frank leukemia to develop, suggesting a
need for additional hit(s) for clinically evident disease to
occur. It is estimated that one child out of 20 is born with a
preleukemic clone [35]. Initiation of disease in utero by
chromosomal translocations exceeds the rate of overt
leukemia by some 100-fold. A similar ratio has been shown
in putative premalignant lesions detected at autopsy by
histopathology, resembling neuroblastoma and Wilms tumor
compared with the actual frequency of clinically evident
Figure 7. Analysis of the ATM C103T Mutation and the VKORC1 G9041A (rs7294) Polymorphism Showing Foreign Origin of the Tumor Cells
(A) MALDI-TOF mass spectrometry of nucleotide 103 of the ATM gene using the SEQUENOM MassArray. C, wild type allele; T, the North African Jewish
ATM mutated allele. F, father’s PB; M, mother’s PB; P-PB, patient’s PB; T, tumor; T-LCM, isolated tumor cells obtained by LCM.
(B) MALDI-TOF mass spectrometry of VKORC1 9041G/A (rs7294) polymorphism using the SEQUENOM MassArray. G/A, SNP at position 9041 (rs7294) of
the VKORC1 gene. F, father’s PB; M, mother’s PB; P-PB, patient’s PB; T, undissected tumor; T-LCM, isolated tumor cells obtained by LCM.
doi:10.1371/journal.pmed.1000029.g007
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common pediatric cancers the occurrence of premalignant
stem/progenitor cells might be very common prenatally, but
the transition to overt disease is rare. This hypothesis may be
relevant to premalignant fetal neural stem cells as well and
should be borne in mind when fetal neural stem cell therapy
is considered.
The only type of malignancy that has been clearly shown to
develop as a result of stem cell therapy in humans is donor
type leukemia following hematopoietic stem cell transplanta-
tion [36]. It appears that donor type leukemia may occur
substantially more frequently with a cord blood source of
stem cells than with adult bone marrow or PB stem cells [36].
Umbilical cord stem cells are more immature than their adult
counterparts. Similarly, one can suggest that the less differ-
entiated fetal neural stem cells are potentially more prone to
transformation than adult neural stem cells.
Stem cell therapy and neural stem cells, in particular,
provide hope to patients affected by devastating diseases.
However, such innovative treatments also carry substantial
risks and the potential for malignant transformation of
transplanted cells has been raised [2,3]. The occurrence of a
donor origin brain tumor in the patient described here
provides the ﬁrst proof that the concerns raised are valid.
Any innovative therapeutic approach carries predictable and
unpredictable risks. For example the impressive success of
gene therapy for children suffering from SCID-X1 was
marred by the occurrence of leukemia resulting from viral
integration leading to oncogene activation [37]. Yet also
‘‘conventional’’ therapies such as chemotherapy, radiother-
apy, and bone marrow transplantation used to treat life
threatening diseases, are associated with morbidity and
mortality. Our ﬁndings therefore do not imply that the
research in stem cell therapeutics should be abandoned. They
do, however, suggest that extensive research into the biology
of stem cells and in-depth preclinical studies, especially of
safety, should be pursued in order to maximize the potential
beneﬁts of regenerative medicine while minimizing the risks.
Supporting Information
Figure S1. Head Coronal Cuts with Gadolinium Injection Showing
the Tentorial Lesion on the Right Side
From (A) 2005 to (B) January 2008, the tumor has grown signiﬁcantly,
more than doubling in volume.
Found at doi:10.1371/journal.pmed.1000029.sg001 (196 KB DOC).
Figure S2. LCM of Tumor Cell Nuclei
(A) High power photomicrograph showing tumor cells intermingled
with small capillaries (hematoxylin–eosine stain, magniﬁcation3400).
Arrows indicate the tumor cells selected for isolation by LCM.
(B) The same section following microdissection of tumor nuclei
(hematoxylin–eosine stain, magniﬁcation3400). Arrows indicate sites
of removed tumor cell nuclei.
Found at doi:10.1371/journal.pmed.1000029.sg002 (264 KB DOC).
Table S1. Oligonucleotides Used for the Detection of the ATM
Mutation and SNPs Using the SEQUENOM MassArray
Found at doi:10.1371/journal.pmed.1000029.st001 (46 KB DOC).
Table S2. Patient’s Recent Immunological and Hematological
Laboratory Data
Found at doi:10.1371/journal.pmed.1000029.st002 (53 KB DOC).
Table S3. Microsatellite Loci Analysis of Patient PB and Tumor Cells
Found at doi:10.1371/journal.pmed.1000029.st003 (27 KB DOC).
Text S1. Protocol for Stem Cell Preparation
Found at doi:10.1371/journal.pmed.1000029.sd001 (26 KB DOC).
Figure 8. Analysis of DNA Tetranucleotide Repeats by Fluorescent PCR and Indicating the Origin of Tumor Cells from at Least Two Donors
(A) Polymorphic pattern of the DNA tetranucleotide repeats of the D18S51, D21S11, D8S117, vWA, D2S1338, and FGA loci as detected by fluorescent
PCR. PB, patient PB; T, tumor.
(B) HLA-A*, B*, and DRB1* typing obtained by reverse-sequence specific oligonucleotide probes (SSOP) using the Luminex platform. The patient’s
germline HLA (determined in PB and BS) are highlighted in red. Nonself alleles are highlighted in black.
doi:10.1371/journal.pmed.1000029.g008
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Background. Most of the cells in the human body are highly specialized
(‘‘differentiated’’). The brain and the spinal cord, for example, contain
two main cell types—neurons, which transmit electrical signals to and
from the brain, and glial cells, which support and protect the neurons. If
these essential neural cells become damaged or diseased, the body
cannot replace them. Scientists think, however, that it might be possible
to use ‘‘neural stem cell’’ transplants to replace the neural cells that are
lost in neurodegenerative diseases (for example, Parkinson’s disease) or
damaged by strokes or trauma. Stem cells are undifferentiated cells that
replicate indefinitely and that have the potential to develop into many
different specialized cells. Pluripotent stem cells (which are able to
develop into any kind of specialized cell) can be isolated from early
human embryos; ‘‘multipotent’’ stem cells (which develop into only a
few cell types) can be isolated from many differentiated tissues,
including the brain. Human fetuses (unborn offspring from the end of
the 8th week after conception) are thought to be a particularly good
source of neural stem cells because many new neural cells are made in
fetal brains.
Why Was This Study Done? Although stem cell transplantation might
provide treatments for many debilitating diseases, some concerns have
been raised over its safety. In particular, some experts fear that tumors
might sometimes develop from transplanted stem cells. Tumor cells
actually behave very much like stem cells—they divide indefinitely and
they tend to be undifferentiated. It is very important, therefore, that
every patient who receives a human stem cell transplant is carefully
followed up to see whether any tumors develop as a result. In this study,
the researchers describe a case in which multiple, slow-growing, donor-
derived brain tumors formed in a patient after the transplantation of
human fetal neural stem cells.
What Did the Researchers Do and Find? Beginning in 2001, fetal neural
stem cells were injected several times into the brain and the fluid
surrounding it of a boy with ataxia telangiectasia at a Moscow hospital.
Ataxia telangiectasia, a rare disorder characterized by degeneration of
the brain region that controls movement and speech, occurs when both
copies of the ATM gene (human cells contain two copies of most genes)
contain a genetic change that stops the production of functional ATM
protein. In 2005, the boy had a magnetic resonance imaging scan at the
Sheba Medical Center (Israel) because of recurrent headaches. The scan
revealed abnormal growths in his brain and spinal cord. In September
2006, when the boy was 14, the spinal cord growth was surgically
removed. This growth has never reappeared but the mass in the boy’s
brain has continued to grow slowly. The material removed from the
boy’s spinal cord contained both neurons and glial cells, the researchers
report, and resembled a glioneuronal tumor. In addition, it contained
both XX (female) and XY (male) cells and the tumor cells had two normal
copies of the ATM gene. Finally, a technique called HLA typing showed
that the tumor contained cells from at least two donors.
What Do These Findings Mean? These findings indicate that the
growth in the patient’s spinal cord was donor-cell derived and contained
cells from two or more donors, at least one of whom was female.
Although the growth in the patient’s brain has not been examined, the
multiple masses seen in this patient probably arose independently from
transplanted cells injected at different sites, suggest the researchers.
Importantly, the slow growth of the tumors and the well-differentiated
appearance of the cells removed from the patient suggest that the
tumors are relatively benign. Donor-derived cells might have been able
to establish tumors in this particular patient because people with ataxia
telangiectasia often have an impaired immune system and the immune
system normally helps to reject tumor cells. Nevertheless, this first
example of a donor-derived brain tumor developing after fetal neural cell
transplantation is worrying and suggests that further work should be
done to assess the safety of this therapy.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
1000029.
 The US National Institutes of Health provides information about stem
cells and their potential uses
 The International Society for Stem Cell Research also provides
information about all aspects of stem cells for the public and for
professionals
 The US National Human Neural Stem Cell Resource provides specific
information about neural stem cells for the public and for scientists
 The US National Cancer Institutes has a fact sheet about ataxia
telangiectasia
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